Title Page

Title of the Manuscript

Screening for Asymptomatic Carotid Artery Stenosis: A Draft Update of the Systematic Review Adapted from the USPSTF Review for the Japanese Preventive Services Task Force

Full names of all authors

Yusuke Saishoji, MD, MHA[1]; Tomoharu Suzuki, MD[2]; Saori Nonaka, MD[3,4]; Shunsuke Suya, MD[5]; Takashi Kitagawa, PhD[6]

Institutional affiliations of all authors

[1]Department of General Medicine, Hakujyuji Hospital, Fukuoka, Japan

[2]Department of Hospital Medicine, Urasoe General Hospital, Okinawa, Japan

[3]Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan

[4]Department of General Medicine, Taito Hospital, Japan Association for Development of Community Medicine, Tokyo, Japan

[5]Department of General Internal Medicine, Hashimoto Municipal Hospital, Wakayama, Japan

[6]Department of Physical Therapy, School of Health Sciences, Shinshu University, Nagano, Japan

Corresponding author

Yusuke Saishoji, MD, MHA

Department of General Medicine, Hakujyuji Hospital,

4-3-1 Ishimaru, Nishi-ku, Fukuoka-shi, Fukuoka, 819-8511, Japan

Telephone Number: +81-92-891-2511

E-mail Address: yusukesaishoji@gmail.com

Word count (for the main text only)

2200

Number of figures

Number of tables

Conflict of Interest

The authors declare no conflicts of interest.

Sources of financial support

This review was conducted as part of the JPPSTF Project, which was financially supported by EVIDENCE STUDIO, a general incorporated association whose purposes include optimizing public

healthcare expenditures in Japan. The funder had no role in the review process, including the collection, analysis, or interpretation of the evidence, or in the decision to submit this manuscript for publication.

Disclaimer

This review was conducted independently of any funding organization. The findings and conclusions expressed herein do not represent the official positions of the authors' affiliated institutions.

Type of contribution of the authors

Study Concept and Design: All authors

Acquisition, Analysis, or Interpretation of Data: All authors

Drafting of the Manuscript: Yusuke Saishoji

Critical Revision of the Manuscript for Important Intellectual Content: Tomoharu Suzuki, Saori Nonaka, Shunsuke Suya, Takashi Kitagawa

Study Supervision: Yusuke Saishoji

Dr. Saishoji had full access to all study data and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

IRB Approval Code and Name of the Institution

Ethical review was deemed unnecessary by The Ethical Committee of Kurume University (health care & medical ethics), as this work is based solely on a literature review and does not involve human subjects or identifiable personal data.

Acknowledgments

Use of AI-assisted tools

During the preparation of this manuscript, an AI-assisted language model (ChatGPT, OpenAI, accessed in 2025) was used to assist in editing and improving the clarity and structure of the text. All content was critically reviewed and finalized by the authors, who take full responsibility for the accuracy and integrity of the manuscript.

Abstract

Background

Carotid artery stenosis is a notable risk factor for ischemic stroke. In 2021, the U.S. Preventive Services Task Force (USPSTF) published an updated evidence review on screening for asymptomatic carotid artery stenosis (ACAS). At the request of the Japan Preventive Services Task Force, we conducted a systematic review to adapt and update the USPSTF review by incorporating recent international evidence and Japanese-language literature.

Methods

Following the USPSTF analytic framework, we evaluated the evidence on screening effectiveness, harms of screening or confirmatory testing, the incremental benefit of revascularization beyond current medical therapy, and harms of surgical interventions in asymptomatic individuals. The International Medical Information Center conducted literature searches in PubMed, the Cochrane Library, and Ichushi-Web. Searches were limited to English and Japanese studies. Two reviewers independently performed study selection, data extraction, and risk of bias assessment, with disagreements resolved by consensus. Newly identified studies were qualitatively synthesized with the 2021 USPSTF findings.

Results

No eligible studies directly assessing the benefits and harms of screening for ACAS were identified. One RCT evaluated the benefits of revascularization, and harms were assessed in that RCT and five observational studies. The RCT (SPACE-2; n=513), which investigated the incremental benefit of revascularization, was terminated prematurely and had substantial methodological limitations. In five registry- or claims-based observational studies, the 30-day incidence of stroke or death following revascularization was 2.5% to 2.8%. Perioperative stroke, death, and myocardial infarction occurred

in 0.9% to 2.3%, 0.3% to 0.9%, and 0.3% to 0.9% of patients, respectively, consistent with the 2021 USPSTF review.

Conclusions

There is no direct evidence evaluating the effectiveness and harms of screening for asymptomatic carotid artery stenosis. Evidence on the benefits and harms of adding revascularization to optimal medical therapy was limited by early trial termination and methodological concerns, reducing the internal validity of the available data.

Keywords

Asymptomatic Carotid Artery Stenosis, Screening, Stroke Prevention, Systematic Review, Revascularization

Background

Carotid artery stenosis is a recognized cause of ischemic stroke [1,2]. In Japan, stroke persists as a leading cause of mortality, highlighting the critical importance of effective prevention strategies for public health. The management of asymptomatic carotid artery stenosis (ACAS) presents a clinical dilemma regarding the appropriateness of preventive intervention.

In 2021, the U.S. Preventive Services Task Force (USPSTF) issued a Grade D recommendation against screening for ACAS in the general asymptomatic adult population [3]. This recommendation was based on the low prevalence of ACAS, the potential harms from false-positive results leading to unnecessary procedures, and the uncertain net benefit of invasive interventions when added to modern medical therapy. However, the applicability of these findings to the Japanese population is not well established. Differences in population demographics, such as advanced aging, alongside variations in stroke incidence, healthcare infrastructure, and screening practices, may alter the benefits and harms of ACAS screening in a Japanese context.

Therefore, this review aimed to provide an up-to-date and objective assessment of the current evidence on the screening and management of asymptomatic carotid artery stenosis in Japanese primary care, with a particular focus on internal validity.

Methods

This study was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [4].

Scope of Review

This review was guided by the analytic framework depicted in Figure 1. The framework and its Key Questions (KQs) were adapted from the 2021 USPSTF evidence review [5] and subsequently revised to align with the Japanese clinical context.

Data Sources and Searches

Literature searches were conducted by the International Medical Information Center. PubMed and the Cochrane Library were searched for studies published in English or Japanese between February 19, 2020, and November 26, 2024. The Ichushi-Web (Japan Medical Abstracts Society) database was searched without restriction on publication date. Detailed search strategies are provided in Table 1.

Study Selection

Two independent reviewers screened titles and abstracts using Rayyan (https://www.rayyan.ai), followed by a full-text review against prespecified eligibility criteria. Disagreements were resolved through discussion. To ensure methodological independence across KQs, reviewer assignments were managed by the designated Literature Review Team. Eligibility criteria were defined separately for each KQ (Table 2). Eligible study designs included randomized controlled trials (RCTs), large-scale cohort studies, systematic reviews, and meta-analyses, depending on the specific question. For KQ1 and KQ3, studies evaluating the effectiveness of screening or revascularization in asymptomatic adults were included. For KQ2 and KQ4, studies were required to report on harms associated with screening, confirmatory testing, or surgical interventions (e.g., carotid endarterectomy (CEA), carotid

artery stenting (CAS)). All studies had to enroll asymptomatic adults without a history of stroke, transient ischemic attack (TIA), or other neurologic symptoms referable to the carotid arteries. Studies limited to symptomatic populations, diagnostic accuracy of screening modalities, or cost-effectiveness were excluded.

Data Extraction and Quality Assessment

Using a standardized form, two reviewers independently extracted relevant data, including study design, population characteristics, intervention, comparator, outcomes, and setting. The risk of bias for each study was assessed independently by two reviewers using design-appropriate tools. The Cochrane Risk of Bias 2 (RoB 2) tool was used for RCTs, and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool was applied to non-randomized intervention studies. For large cohort or registry-based studies, a modified Newcastle-Ottawa Scale was used. All disagreements in data extraction or quality assessment were resolved by consensus. Risk of bias was assessed using three tools: RoB 2 categorized studies as having "Low," "Some concerns," or "High" risk of bias; ROBINS-I used four categories—"Low," "Moderate," "Serious," and "Critical"; and the Newcastle-Ottawa Scale classified study quality as "Poor," "Fair," or "Good."

Data Synthesis and Analysis

Findings from newly identified studies were qualitatively synthesized alongside the evidence from the 2021 USPSTF review [5]. A meta-analysis was not performed in this review, as a relatively recent systematic review conducted by the United States Preventive Services Task Force (USPSTF) was available, and it comprehensively addressed the key outcomes relevant to our review. Additionally, due to the need to complete the review within a limited timeframe for policy relevance, we prioritized a narrative synthesis. For each KQ, results were summarized in descriptive text and tables, focusing on the direction and consistency of findings, study design, and methodological quality.

Results

Summary of Evidence Search and Selection

The literature search yielded 764 records. After the removal of duplicates, 666 titles and abstracts were screened. (PRISMA flow diagrams for each KQ are available in Figure 2). No studies met the criteria for full-text review for KQ1 (benefits of screening) or KQ2 (harms of screening). For KQ3 (benefits of revascularization) and KQ4 (harms of revascularization), 6 and 27 studies underwent full-text review, respectively. Ultimately, 1 RCT [6] and 5 observational studies [7-11] were included in the final synthesis. A detailed list of included studies and their findings is provided in Table 3.

Results of Included Studies

Benefits of Screening

Key Question 1. Does ultrasound screening for carotid artery stenosis in asymptomatic adults improve health outcomes?

No RCTs evaluating the benefits of screening for ACAS were identified within the protocol-defined search period.

Harms of Screening

Key Question 2. What are the harms associated with screening and confirmatory testing for asymptomatic carotid artery stenosis?

No RCTs assessing the harms of screening for ACAS were identified within the protocol-defined search period.

Incremental Benefits of Revascularization

Key Question 3. Does adding surgical treatment to current medical therapy provide additional benefit for patients with asymptomatic carotid artery stenosis?

A single RCT was identified that assessed the incremental benefits of revascularization for ACAS [6]. The SPACE-2 trial, a 3-arm parallel-group study, enrolled 513 participants comparing CEA plus best medical therapy (BMT), CAS plus BMT, and BMT alone. The study reported on outcomes including stroke, mortality, and functional status but did not assess quality of life or cognitive function. The cumulative 5-year incidence of stroke or death within 30 days was 2.5% in the CEA+BMT group, 4.4% in the CAS+BMT group, and 3.1% in the BMT-alone group; these differences were not statistically significant. When considering ipsilateral ischemic stroke alone, the 5-year cumulative incidence was 2.0% for CEA plus BMT, 4.4% for CAS plus BMT, and 3.1% for BMT alone. Although the incidence was slightly lower in the CEA group, the differences were not statistically significant. Similarly, there were no statistically significant differences in all-cause mortality (7.6% for CEA+BMT, 9.3% for CAS+BMT, and 8.0% for BMT alone) or the cumulative incidence of stroke with a modified Rankin Scale score >2 at 30 days (1.0%, 1.7%, and 2.0%, respectively). This study was judged to be at a high risk of bias (Figure 3).

Harms of Revascularization

Key Question 4. What are the harms associated with surgical treatment for asymptomatic carotid artery stenosis?

One RCT [6] (also included in KQ3) and 5 observational studies [7-11] were identified.

Stroke or Death Within 30 Days: Three studies reported this composite outcome. The RCT by Reiff et al. [6] found no statistically significant difference between CEA or CAS compared to BMT. Two large

retrospective cohort studies reported incidences of 2.5% [10] and 2.8% [11], respectively, though neither included a non-surgical comparator group.

Stroke or Death Within 1 Year: One large registry-based study (n=8,460) reported a 1.2% incidence of this outcome among patients undergoing transcarotid artery revascularization (TCAR) [8].

Stroke (Perioperative or Long-Term): Six studies reported on stroke as a harm. The RCT showed no statistically significant difference between the intervention and control groups [6]. Incidence rates in the observational studies ranged from 0.9% to 7.5% [8-11].

Death: Five studies addressed this outcome. The RCT found no statistically significant differences [6]. Mortality rates in the observational studies were 0.3% [8], 0.7% [9], and 0.9% [11].

Myocardial Infarction (MI): Four studies reported MI rates. The RCT [6] found no statistically significant differences, and 3 observational studies reported rates from 0.3% to 0.9% [8, 9, 11].

Cranial Nerve Injury: One study [8] reported a 0.1% incidence of cranial nerve injury following TCAR.

Other outcomes evaluated in the randomized controlled trial by Reiff et al. [6] included ipsilateral stroke, ischemic stroke, disabling stroke, ipsilateral disabling stroke, ischemic stroke or vascular death, restenosis and progression of stenosis, vascular death, transient ischemic attack (TIA), and ipsilateral TIA. For all of these outcomes, no statistically significant differences were observed in either relative or absolute risk between CEA and CAS.

The risk of bias assessments for the 5 observational studies are summarized in Table 4.

Discussion

Summary of Findings

In 2021, the USPSTF recommended against screening for ACAS in the general population (Grade D), concluding that the potential benefits do not outweigh the harms [5]. This review aimed to provide an up-to-date and objective evaluation of the current evidence on screening and management of asymptomatic carotid artery stenosis (ACAS) in Japanese primary care, with a focus on internal validity. However, no eligible studies were identified that directly assessed the benefits or harms of ACAS screening. The available evidence on treatment is also limited. The single RCT that assessed the incremental benefit of revascularization (SPACE-2) was terminated prematurely and possessed substantial methodological limitations, including a high risk of bias [6]. In five registry- or claims-based observational studies [7-11], the 30-day incidence of stroke or death following revascularization was 2.5% to 2.8%. Perioperative stroke, death, and myocardial infarction occurred in 0.9% to 2.3%, 0.3% to 0.9%, and 0.3% to 0.9% of patients, respectively. These findings were consistent with the conclusions of the 2021 USPSTF review.

The internal validity of the studies included in this systematic review was limited by variations in risk estimation and outcome assessment methods across studies, potentially affecting the reliability of their findings. The RCT by Reiff et al. [6] suffered from a small sample size and high attrition, undermining its statistical power and introducing potential selection bias. Furthermore, it was judged to be at high risk of bias due to deviations from the intended intervention and issues with missing outcome data, raising concerns about the reliability of its findings. The wide confidence intervals for both relative and absolute risks indicate substantial uncertainty. Among the observational studies, several lacked appropriate comparator groups and had inadequate adjustment for confounding, limiting causal inference [10, 11]. The study by Poorthuis et al. [11] did not adjust for any prognostic variables. In contrast, studies by Goicoechea et al. [9], Deery et al. [8], and Chang et al. [7] employed more rigorous methods for

confounding adjustment and were thus considered to have higher internal validity. Regarding the

reliability of outcome assessment, RCT were subject to risks such as lack of blinding, while

retrospective studies often had limitations in consistency and objectivity of outcome evaluation. In

particular, rare outcomes such as surgery-related complications and cranial nerve injury may be prone

to reporting bias. Furthermore, the Vascular Quality Initiative (VQI) database used in the study by

Deery et al. was based on clinical data from selected hospitals, physicians, and cases.

Overall, the internal validity of the studies included in this review was subject to several limitations,

including small sample sizes and high attrition rates in RCTs, as well as sample bias, absence of

comparison groups, and inadequate adjustment for confounding in retrospective observational studies.

Limitations

This review has several important limitations. First, the absence of eligible published studies

involving Japanese populations precludes a direct assessment of the effectiveness or harm of ACAS

screening in Japan. The review relied on studies conducted primarily in Western countries, whose

populations may differ from Japan's in terms of genetic background, healthcare systems, and risk

factor profiles. While one Japanese study assessing the safety of CAS in elderly patients [12] was

excluded due to small sample size, its finding of a 1.85% incidence of major stroke, myocardial

infarction, or death within 30 days post-CAS aligns with the range reported in this review. In addition,

although the literature search in Ichushi-Web did not impose a publication date restriction, studies

published before February 19, 2020, were excluded at the full-text screening stage based on the

protocol-defined eligibility criteria. One such study was the Japan Carotid Atherosclerosis Study

(JCAS) [13], a large multicenter prospective registry conducted in Japan. Although JCAS formally met

the threshold for a "fair" quality rating under the modified Newcastle-Ottawa Scale, the absence of

any adjustment for confounding variables (0 points for comparability), along with the potential for

selection bias, raised concerns regarding its internal validity. Including this study in the evidence synthesis would not have altered the overall conclusions of the review.

Second, this review focused on procedural harms (e.g., stroke, death), but did not systematically assess non-physical harms such as the psychological burden of a new diagnosis, overdiagnosis, or the resource utilization associated with screening programs.

Third, the included studies often had long data collection periods. Continuous advancements in both medical therapy (e.g., high-intensity statins) and surgical techniques may have lowered event rates in contemporary practice, potentially altering the risk-benefit from what is reported in the literature.

Conclusions

There is a lack of direct evidence evaluating the effectiveness and harms of screening for asymptomatic carotid artery stenosis. Furthermore, the evidence regarding the benefits and harms of adding revascularization to optimal medical therapy is limited by early termination of trials and methodological limitations, thereby reducing the internal validity and warranting cautious interpretation of the findings.

References

1. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 2000;342(23):1693-700.

2. Chang RW, Tucker LY, Rothenberg KA, et al. Incidence of Ischemic Stroke in Patients With Asymptomatic Severe Carotid Stenosis Without Surgical Intervention. JAMA. 2022;327(20):1974-82.

3. Force USPST, Krist AH, Davidson KW, et al. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(5):476-81.

4. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.

5. Guirguis-Blake JM, Webber EM, Coppola EL. Screening for Asymptomatic Carotid Artery Stenosis in the General Population: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(5):487-9.

6. Reiff T, Eckstein HH, Mansmann U, et al. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Lancet Neurol. 2022;21(10):877-88.

7. Chang RW, Pimentel N, Tucker LY, et al. A comparative effectiveness study of carotid intervention for long-term stroke prevention in patients with severe asymptomatic stenosis from a large integrated health system. J Vasc Surg. 2023;78(5):1239-47 e4.

8. Deery SE, Holscher CM, Nejim B, et al. In-hospital and one-year outcomes are similar for women and men following transcarotid artery revascularization in symptomatic and asymptomatic patients. J Vasc Surg. 2022;75(2):572-80 e3.

9. Goicoechea S, Walsh M, Soult M, et al. Female gender increases risk of stroke and readmission

after carotid endarterectomy and carotid artery stenting. J Vasc Surg. 2022;75(6):1935-44.

10. Keyhani S, Cheng EM, Hoggatt KJ, et al. Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis. JAMA Neurol. 2020;77(9):1110-21.

11. Poorthuis MHF, Bulbulia R, Morris DR, et al. Timing of procedural stroke and death in asymptomatic patients undergoing carotid endarterectomy: individual patient analysis from four RCTs. Br J Surg. 2020;107(6):662-8.

12. Taguchi A, Sakamoto S, Okazaki T, et al. Safety of carotid artery stenting for elderly patients with cervical carotid artery stenosis. Interv Neuroradiol. 2020;26(4):439-45.

13. Endo S, Kuwayama N, Hirashima Y, et al. Japan Carotid Atherosclerosis Study: JCAS. Neurol Med Chir (Tokyo). 2004;44(4):215-7.

Figure 1. Analytic Framework: Screening for Asymptomatic Carotid Artery Stenosis

Table 1. Search strategies

MEDLINE (via PubMed) search strategy

#1	"CAROTID STENOSIS"[MESH] OR "CAROTID STENOSES"[TITLE/ABSTRACT:~3] OR "CAROTID STENOSIS"[TITLE/ABSTRACT:~3] OR "CAROTID ATHEROSCLEROSES"[TITLE/ABSTRACT:~3] OR "CAROTID ATHEROSCLEROSIS"[TITLE/ABSTRACT:~3] OR "CAROTID NARROWING"[TITLE/ABSTRACT:~3] OR "CAROTID NARROWINGS"[TITLE/ABSTRACT:~3] OR "CAROTID ULCER"[TITLE/ABSTRACT:~3] OR "CAROTID ULCERS"[TITLE/ABSTRACT:~3] OR "CAROTID PLAQUE"[TITLE/ABSTRACT:~3] OR "CAROTID PLAQUES"[TITLE/ABSTRACT:~3]
#2	RANDOMIZED CONTROLLED TRIAL[PT] OR PRAGMATIC CLINICAL TRIAL[PT] OR "RANDOM ALLOCATION"[MESH] OR "SINGLE-BLIND METHOD"[MESH] OR "DOUBLE-BLIND METHOD"[MESH] OR "SINGLE BLIND"[TITLE/ABSTRACT:~1] OR "DOUBLE BLIND"[TITLE/ABSTRACT:~1] OR "TREBLE BLIND"[TITLE/ABSTRACT:~1] OR "TRIPLE BLIND"[TITLE/ABSTRACT:~1] OR "SINGLE MASK"[TITLE/ABSTRACT:~1] OR "DOUBLE MASK"[TITLE/ABSTRACT:~1] OR "TREBLE MASK"[TITLE/ABSTRACT:~1] OR "TRIPLE MASK"[TITLE/ABSTRACT:~1] OR "RANDOM*"[TIAB] OR "PRAGMATIC STUDY"[TITLE/ABSTRACT:~3] OR "PRAGMATIC STUDIES"[TITLE/ABSTRACT:~3] OR "PRAGMATIC TRIAL"[TITLE/ABSTRACT:~3] OR "PRAGMATIC TRIALS"[TITLE/ABSTRACT:~3] OR "PRAGMATIC TEST"[TITLE/ABSTRACT:~3] OR "PRAGMATIC TESTS"[TITLE/ABSTRACT:~3] OR "PLACEBO*"[TIAB] OR "LARGE SCALE STUDY"[TITLE/ABSTRACT:~4] OR "LARGE SCALE STUDIES"[TITLE/ABSTRACT:~4] OR "LARGE SCALE TRIAL"[TITLE/ABSTRACT:~4] OR "LARGE SCALE TRIALS"[TITLE/ABSTRACT:~4] OR "LARGE SCALE COHORT"[TITLE/ABSTRACT:~4] OR "LARGE SCALE REGISTRY"[TITLE/ABSTRACT:~4] OR SYSTEMATIC REVIEW[PT] OR META-ANALYSIS[PT] OR "SYSTEMATIC REVIEW"[TITLE/ABSTRACT:~2] OR "SYSTEMATIC OVERVIEW"[TITLE/ABSTRACT:~2] OR "META ANALY*"[TIAB] OR "METAANAL*"[TIAB] OR "METANAL*"[TIAB] OR "INTEGRATIVE RESEARCH REVIEW"[TITLE/ABSTRACT:~3] OR "RESEARCH INTEGRATION"[TITLE/ABSTRACT:~3]
#3	#1 AND #2
#4	#3 AND ("ADULT"[MESH] OR "YOUNG ADULT"[MESH] OR "MIDDLE AGED"[MESH] OR "AGED"[MESH] OR "AGED, 80 AND OVER"[MESH] OR ADULT*[TIAB] OR AGED[TIAB] OR ELDERLY[TIAB] OR SENIUM[TIAB])
#5	#4 AND 2020/02/19:2024/11/24[DATE - PUBLICATION]
#6	#5 AND ("ENGLISH"[LANGUAGE] OR "JAPANESE"[LANGUAGE])

CENTRAL search strategy

#1	[mh "CAROTID STENOSIS"] OR (CAROTID* NEAR/3 (STENOS* OR ATHEROSCLERO* OR NARROW* OR ULCER* OR PLAQUE*)):TI,AB,KW
#2	[mh "RANDOM ALLOCATION"] OR [mh "SINGLE-BLIND METHOD"] OR [mh "DOUBLE-BLIND METHOD"] OR ((SINGL* OR DOUBLE* OR TREBL* OR TRIPL*) NEXT (BLIND* OR MASK*) OR RANDOM* OR PRAGMATIC* NEAR/3 (STUD* OR TRIAL* OR TEST*) OR PLACEBO* OR LARGE NEXT SCALE NEAR/3 (STUD* OR TRIAL* OR COHORT* OR REGISTRY*) OR SYSTEMATIC* NEAR/2 (REVIEW* OR OVERVIEW*) OR META NEXT ANALY* OR METAANAL* OR METANAL* OR INTEGRATIVE* NEAR/1 RESEARCH* NEAR/1 REVIEW* OR RESEARCH* NEAR/1 INTEGRATION*)):TI,AB,KW
#3	#1 AND #2
#4	[mh "ADULT"] OR [mh "YOUNG ADULT"] OR [mh "MIDDLE AGED"] OR [mh "AGED"] OR [mh "AGED, 80 AND OVER"] OR (ADULT* OR AGED OR ELDERLY OR SENIUM):TI,AB,KW
#5	#3 AND #4
#6	#5 with Publication Year from 2020 to 2024, in Trials
#7	#5 with Cochrane Library publication date Between Feb 2020 and Nov 2024, in Cochrane Reviews, Cochrane Protocols, Clinical Answers, Editorials, Special Collections
#8	ENGLISH:LA OR JAPANESE:LA
#9	(#6 OR #7) AND #8

Ichushi-Web search strategy

#1	頸動脈狭窄/TH or ((CAROTID/AL or 頸動脈/AL or 頸部動脈/AL or 頚動脈/AL or 頚部動脈/AL) and (STENOS/AL or ATHEROSCLERO/AL or NARROW/AL or ULCER/AL or PLAQUE/AL or 狭窄/AL or 閉塞/AL))
#2	(RD=ランダム化比較試験) or (RD=準ランダム化比較試験) or ランダム化比較試験/TH or 準ランダム化比較試験/TH or ランダム割付け/TH or 一重盲検法/TH or 二重盲検法/TH or プラセボ/TH or ランダム/AL or ランダマイ/AL or 無作為/AL or 盲検/AL or ブラインド/AL or シングルマスク/AL or シングル・マスク/AL or ダブルマスク/AL or ダブル・マスク/AL or トリプルマスク/AL or トリプル・マスク/AL or 実際的試験/AL or 実際的研究/AL or 実践的試験/AL or 実践的研究/AL 実用的試験/AL or 実用的研究/AL or 実際的臨床試験/AL or 実際的臨床研究/AL or 実践的臨床試験/AL or 実践的臨床研究/AL or 実用的臨床試験/AL or 実用的臨床研究/AL or プラグマティック試験/AL or プラグマティック研究/AL or プラグマチック試験/AL or プラグマチック研究/AL or プラセボ/AL or プラシーボ/AL or 偽薬/AL or 偽剤/AL or RANDOM/AL or BLIND/AL or "SINGLE MASK"/AL or SINGLE-MASK/AL or "DOUBLE MASK"/AL or DOUBLE-MASK/AL or "TRIPLE MASK"/AL or TRIPLE-MASK/AL or "TREBLE MASK"/AL or TREBLE-MASK/AL or "PRAGMATIC TRIAL"/AL or "PRAGMATIC CLINICAL TRIAL"/AL or "PRAGMATIC STUD"/AL or "PRAGMATIC CLINICAL STUD"/AL or PLACEBO/AL or 大規模臨床/AL or 大規模試験/AL or 大規模研究/AL or 大規模コホート/AL or 大規模登録/AL or 大規模レジストリ/AL or "LARGE SCALE STUD"/AL or "LARGE SCALE TRIAL"/AL or "LARGE SCALE COHORT"/AL or "LARGE SCALE REGISTRY"/AL or システマティックレビュー/TH or コホート研究/TH or システマティックレビュ/AL or システマチックレビュ/AL or システマティック・レビュ/AL or システマチック・レビュ/AL or システマティックレヴュ/AL or システマチックレヴュ/AL or システマティック・レヴュ/AL or システマチック・レヴュ/AL or 系統的レビュ/AL or 系統的にレビュ/AL or 系統的なレビュ/AL or 系統レビュ/AL or 系統的レヴュ/AL or 系統的にレヴュ/AL or 系統的なレヴュ/AL or 系統レヴュ/AL or 体系的レビュ/AL or 体系的にレビュ/AL or 体系的なレビュ/AL or 体系的レヴュ/AL or 体系的にレヴュ/AL or 体系的なレヴュ/AL or 系統的考察/AL or 系統的に考察/AL or 系統的な考察/AL or 体系的考察/AL or 体系的に考察/AL or 体系的な考察/AL or "SYSTEMATIC REVIEW"/AL or SYSTEMATIC-REVIEW/AL or "SYSTEMATICAL REVIEW"/AL or SYSTEMATICAL-REVIEW/AL or "SYSTEMATIC OVERVIEW"/AL or SYSTEMATIC-OVERVIEW/AL or "SYSTEMATICAL OVERVIEW"/AL or SYSTEMATICAL-OVERVIEW/AL or RD=メタアナリシス or メタアナリシス/TH or メタ分析/AL or メタアナ/AL or メタ・アナ/AL or メタ解析/AL or メタ研究/AL or META-ANALYS/AL or "META ANALYS"/AL or METAANALYS/AL or METANALYS/AL or META 解析/AL or META 分析/AL or META 研究/AL or "INTEGRATIVE RESEARCH REVIEW"/AL or "RESEARCH INTEGRATION"/AL
#3	#1 and #2

#4	成人/TH or 中年/TH or 高齢者/TH or ADULT/AL or AGED/AL or ELDERLY/AL or SENIUM/AL or おとな/AL or 成人/AL or 中年/AL or 中高年/AL or 熟年/AL or 壮年/AL or 高齢/AL or 高令/AL or 老人/AL or 長寿者/AL or 高年者/AL or 高年齢/AL or 高年令/AL or 老年/AL or 老齢/AL or 初老/AL or 老令/AL or (CK=成人(19〜44),中年(45〜64),高齢者(65〜),高齢者(80〜))
#5	#3 and #4
#6	#5 and (DT=1903:2024)
#7	#6 and (LA=日本語,英語)

Table 2. Eligibility criteria were defined separately for each Key Question (KQ)

KQ 1. Does ultrasound screening for carotid artery stenosis in asymptomatic adults improve health outcomes?

Category	Inclusion Criteria	Exclusion Criteria
Population	Asymptomatic adults (i.e., no carotid-related neurological symptoms, no history of stroke or TIA)	Children and adolescents; adults with symptomatic carotid stenosis; adults with history of stroke or TIA Individuals with known carotid occlusion or CVD; those undergoing CAS preoperative planning; those who underwent CEA or CAS and are monitored for restenosis
Screening Methods	Carotid ultrasound screening	Carotid bruit examination; CIMT measurement for cardiovascular risk prediction
Comparator	No screening	
Outcomes	Stroke related to carotid stenosis, mortality, quality of life, functional status, cognitive function	Diagnostic accuracy, Cardiovascular disease risk prediction
Study Design	RCTs	Cost-effectiveness analyses, All non-RCTs
Study Quality	Studies rated as Good or Fair based on standard risk-of-bias tools and USPSTF criteria, adjusted by study design	Poor quality studies
Publication Date	February 19, 2020, to present	
Language	Japanese, English	

TIA: transient ischemic attack, CVD: cardiovascular disease, CAS: carotid artery stenting, CEA: carotid endarterectomy, CIMT: carotid intima-media thickness, RCT: randomized controlled trial, USPSTF: U.S. Preventive Services Task Force

KQ 2. What are the harms associated with screening and confirmatory testing for asymptomatic carotid artery stenosis?

Category	Inclusion Criteria	Exclusion Criteria
Population	Asymptomatic adults (i.e., no carotid-related neurological symptoms, no history of stroke or TIA)	Children and adolescents; adults with symptomatic carotid stenosis; adults with history of stroke or TIA Individuals with known carotid occlusion or CVD; those undergoing CAS preoperative planning; those who underwent CEA or CAS and are monitored for restenosis
Screening Methods	Carotid ultrasound screening	Carotid bruit examination; CIMT measurement for cardiovascular risk prediction
Comparator	No screening	
Outcomes	Stroke related to carotid stenosis, mortality, quality of life, functional status, cognitive function	Diagnostic accuracy, Cardiovascular disease risk prediction
Study Design	RCTs	Cost-effectiveness analyses, All non-RCTs
Study Quality	Studies rated as Good or Fair based on standard risk-of-bias tools and USPSTF criteria, adjusted by study design	Poor quality studies
Publication Date	February 19, 2020, to present	
Language	Japanese, English	

TIA: transient ischemic attack, CVD: cardiovascular disease, CAS: carotid artery stenting, CEA: carotid endarterectomy, CIMT: carotid intima-media

thickness, RCT: randomized controlled trial, USPSTF: U.S. Preventive Services Task Force

KQ 3. Does adding surgical treatment to current medical therapy provide additional benefit for patients with asymptomatic carotid artery stenosis?

Category	Inclusion Criteria	Exclusion Criteria
Population	Asymptomatic adults with clinically significant carotid stenosis (60–99% stenosis)	Children and adolescents; adults with symptomatic carotid stenosis; adults with history of stroke or TIA
Interventions	Surgical treatments including CEA, CAS, TCAR	
Comparator	Medical therapy or usual care (e.g., statins, antiplatelet agents)	Comparisons between CEA and CAS
Outcomes	Stroke related to carotid stenosis, mortality, quality of life, functional status, cognitive function	
Study Design	RCTs	Cost-effectiveness analyses, All non-RCTs
Study Quality	Studies rated as Good or Fair based on standard risk-of-bias tools and USPSTF criteria, adjusted by study design	Poor quality studies
Publication Date	February 19, 2020, to present	
Language	Japanese, English	

TIA: transient ischemic attack, CEA: carotid endarterectomy, CAS: carotid artery stenting, TCAR: transcarotid artery revascularization, RCT: randomized controlled trial, USPSTF: U.S. Preventive Services Task Force

KQ 4. What are the harms associated with surgical treatment for asymptomatic carotid artery stenosis?

Category	Inclusion Criteria	Exclusion Criteria
Population	Asymptomatic adults with clinically significant carotid stenosis (60–99% stenosis)	Children and adolescents; adults with symptomatic carotid stenosis; adults with history of stroke or TIA
Interventions	Surgical treatments including CEA, CAS, TCAR	
Comparator	Medical therapy or usual care; or non-comparative studies reporting adverse event rate	Comparisons between CEA and CAS
Outcomes	Surgical complications (e.g., stroke, mortality, MI, CNI)	
Study Design	RCTs, large cohort studies or registry studies	Cost-effectiveness analyses, Case reports, Small observational studies
Study Quality	Registered Studies Initial Eligibility Criteria (・More than 10,000 cases of asymptomatic surgeries・Data from the United States and Japan ・Large-scale national administrative databases or small-scale surgical registries) Audit Priority Criteria (・The primary study should be the largest and most recent population-based study (If there is a newer but smaller study, it should be included as a supplementary article to compare trends or similarities) ・Results are stratified by symptom status ・If no studies stratify results by symptom status, select studies in which asymptomatic cases account for 80% or more)	Poor quality studies
Publication Date	February 19, 2020, to present	
Language	Japanese, English	

TIA: transient ischemic attack, CEA: carotid endarterectomy, CAS: carotid artery stenting, TCAR: transcarotid artery revascularization, MI: myocardial

infarction, CNI: cranial nerve injury, RCT: randomized controlled trial

Figure 2. PRISMA flow diagrams for each Key Question (KQ)

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources (KQ1)

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

This work is licensed under CC BY 4.0. To view a copy of this license, visit
https://creativecommons.org/licenses/by/4.0/

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources (KQ2)

Identification	**Previous studies**	**Identification of new studies via databases and registers**	**Identification of new studies via other methods**

Studies included in previous version of review (n = 0)

Reports of studies included in previous version of review (n = 0)

Records identified from*:
  Ichushi-Web (n = 134)
  PubMed (n = 293)
  Cochrane Library (n = 337)

Records removed *before screening*:
  Duplicate records removed (n = 98)

Records identified from:
  Websites (n = 0)
  Organisations (n = 0)
  Citation searching (n = 0)
  etc.

Screening

Records screened (n = 666)

Records excluded** (n = 666)

Reports sought for retrieval (n = 666)

Reports not retrieved (n = 0)

Reports sought for retrieval (n = 0)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 0)

Reports excluded (n = 0)

Reports assessed for eligibility (n = 0)

Reports excluded (n = 0)

New studies included in review (n = 0)
Reports of new included studies (n = 0)

Included

Total studies included in review (n = 0)
Reports of total included studies (n = 0)

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources (KQ3)

Previous studies

Identification of new studies via databases and registers

Identification of new studies via other methods

Identification

Studies included in previous version of review (n = 0)

Reports of studies included in previous version of review (n = 0)

Records identified from*:
Ichushi-Web (n = 134)
PubMed(n = 293)
Cochrane Library (n = 337)

Records removed *before screening*:
Duplicate records removed (n = 98)

Records identified from:
Websites (n = 0)
Organisations (n = 0)
Citation searching (n = 0)
etc.

Screening

Records screened (n = 666)

Records excluded** (n = 660)

Reports sought for retrieval (n = 6)

Reports not retrieved (n = 0)

Reports sought for retrieval (n = 0)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 6)

Reports excluded:
Wrong study design (n = 2)
Abstract (n = 2)
Protocol without results (n = 1)

Reports assessed for eligibility (n = 0)

Reports excluded (n = 0)

Included

New studies included in review (n = 1)
Reports of new included studies (n = 0)

Total studies included in review (n = 1)
Reports of total included studies (n = 0)

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

This work is licensed under CC BY 4.0. To view a copy of this license, visit
https://creativecommons.org/licenses/by/4.0/

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources (KQ4)

Previous studies	Identification of new studies via databases and registers	Identification of new studies via other methods

Identification

Studies included in previous version of review (n = 0)

Reports of studies included in previous version of review (n = 0)

Records identified from*:
Ichushi-Web (n = 134)
PubMed(n = 293)
Cochrane Library (n = 337)

Records removed *before screening*:
Duplicate records removed (n = 98)

Records identified from:
Websites (n = 0)
Organisations (n = 0)
Citation searching (n = 0)
etc.

Screening

Records screened (n = 666)

Records excluded** (n = 639)

Reports sought for retrieval (n = 27)

Reports not retrieved (n =0)

Reports sought for retrieval (n = 0)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 27)

Reports excluded:
Small scale (n = 10)
Abstract (n = 5)
Protocol without results (n = 2)
Wrong population (n = 1)
Wrong control (n = 1)
Wrong outcome (n = 1)
Wrong language (n = 1)

Reports assessed for eligibility (n = 0)

Reports excluded (n = 0)

Included

New studies included in review (n =6)
Reports of new included studies (n = 0)

Total studies included in review (n = 6)
Reports of total included studies (n = 0)

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

Table 3. Detailed list of included studies

Study	Study design	Country	Type of Surgical Procedure	Follow-up Duration	Setting and Study Population	No. of ACAS Participants	Primary Outcome(s)	RoB	COI Disclosure
Reiff, 2022	RCT	Austria Germany Switzerland	CEA CAS	5years	ACAS of 50–70% or more	513	Stroke or cerebral infarction within 30 days Ipsilateral stroke within 5 years	High	Disclosures reported Funding reported
Keyhani, 2020	Cohort	USA	CEA	5years	ACAS (≥70%) from the US Department of VA and Medicare data	5221	Ipsilateral stroke	Fair	No disclosures reported
Poorthuis, 2020	Cohort	USA Canada Europe	CEA	30days	Individual patient data from four RCTs targeting ACAS ≥50%	3694	Stroke and death	Fair	Disclosures reported Funding reported
Goicoechea, 2022	Cohort	USA	CEA CAS	30days	ACS NSQIP*	100637	Stroke	Good	Disclosures reported
Deery, 2021	Cohort	USA	TCAR	30days	Carotid artery stenosis ≥70% in the US VQI	8460	Stroke, death, and myocardial infarction within 30 days	Good	Disclosures reported
Chang, 2023	Cohort	USA	CEA	5years	ACAS ≥70% in KPNC	3824	Stroke	Good	Disclosures reported

ACAS: asymptomatic carotid artery stenosis, RoB: risk of bias, COI: conflict of interest disclosure, RCT: randomized controlled trial, CEA: carotid endarterectomy, CAS: carotid artery stenting, VA: Veterans Affairs, ACS NSQIP: American College of Surgeons National Surgical Quality Improvement Program, VQI: Vascular Quality Initiative, KPNC: Kaiser Permanente Northern California, * Degree of stenosis not reported.

Figure 3. Risk of bias for the randomized clinical trial

Risk of bias domains

	D1	D2	D3	D4	D5	Overall
Reiff, 2022	+	X	X	+	+	X

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement

X High

+ Low

Table 4. Risk of bias assessments for the five observational studies

	Representativeness of exposed cohort	Selection of non-exposed cohort	Ascertainment of exposure	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Adequacy of follow up	Score and levels of evidence
Keyhani, 2020	★	0	★	★★	★	★	6, Fair
Poorthuis, 2020	★	0	★	0	★	★	4, Fair
Goicoechea, 2022	★★	★	★	0	★	★★	7, Good
Deery, 2021	★★	★	★	★	★	★★	8, Good
Chang, 2023	★★	★	★	★★	★	★★	9, Good